Probiotic neoantigen delivery vectors for precision cancer immunotherapy
Andrew Redenti(Columbia University), Nicholas Arpaia(Columbia University Irving Medical Center), Rosa L. Vincent(Columbia University), YoungUk Jang(Icahn School of Medicine at Mount Sinai), Fangda Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jongwon Im(Columbia University), Tal Danino(Herbert Irving Comprehensive Cancer Center), Candice R. Gurbatri(Tempus Labs (United States)), Edward R. Ballister(Columbia University), Meghna Komaranchath(Columbia University), William Sun(Incyte (United States)), Ana Vardoshivilli(Columbia University), Benjamin Redenti(Columbia University), Zeren Sheng(Columbia University), Mathieu Rouanne(Université de Versailles Saint-Quentin-en-Yvelines), Shunyu Huang(Columbia University), Jaeseung Hahn(Columbia University)
Cited by 164
Related Papers
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
|Biology of Blood and Marrow Transplantation|2015|762
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
|Science Translational Medicine|2020|600
Engineering bacteria as interactive cancer therapies
|Science|2022|411